"For the millions of people who suffer from atopic dermatitis (AD), or eczema, ENS-002 represents a potential paradigm shift in care." Current treatments like steroids and immunosuppressants may come ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Opens in a new tab or window Higher-potency topical corticosteroids, JAK inhibitors, and tacrolimus 0.1% were deemed the most effective topical anti-inflammatory treatments for atopic dermatitis ...

It is not just about itchy skin: Know surprising truth about Atopic Dermatitis as Eczema is on the rise in ... has led to the development of targeted treatments, offering help for individuals ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.